Stenotrophomonas, Achromobacter, and Nonmelioid Burkholderia Species: Antimicrobial Resistance and Therapeutic Strategies
暂无分享,去创建一个
[1] Glen R. Brown. Cotrimoxazole - optimal dosing in the critically ill , 2014, Annals of Intensive Care.
[2] Roopali Sharma,et al. The role of tigecycline in the treatment of infections in light of the new black box warning , 2014, Expert review of anti-infective therapy.
[3] S. Schippa,et al. Outbreak of Achromobacter xylosoxidans in an Italian Cystic fibrosis center: genome variability, biofilm production, antibiotic resistance, and motility in isolated strains , 2014, Front. Microbiol..
[4] M. Skov,et al. Early treatment with inhaled antibiotics postpones next occurrence of Achromobacter in cystic fibrosis. , 2013, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[5] J. Papadopoulos,et al. Monotherapy with Fluoroquinolone or Trimethoprim-Sulfamethoxazole for Treatment of Stenotrophomonas maltophilia Infections , 2013, Antimicrobial Agents and Chemotherapy.
[6] K. Peck,et al. Can Levofloxacin Be a Useful Alternative to Trimethoprim-Sulfamethoxazole for Treating Stenotrophomonas maltophilia Bacteremia? , 2013, Antimicrobial Agents and Chemotherapy.
[7] C. Neuwirth,et al. Detection of Achromobacter xylosoxidans in Hospital, Domestic, and Outdoor Environmental Samples and Comparison with Human Clinical Isolates , 2013, Applied and Environmental Microbiology.
[8] S. Sørensen,et al. Complete Genome Sequence of the Cystic Fibrosis Pathogen Achromobacter xylosoxidans NH44784-1996 Complies with Important Pathogenic Phenotypes , 2013, PloS one.
[9] Amit Arora,et al. Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry: a Fundamental Shift in the Routine Practice of Clinical Microbiology , 2013, Clinical Microbiology Reviews.
[10] Brian M. Owens. Silver makes antibiotics thousands of times more effective , 2013, Nature.
[11] B. Duffy,et al. The Culturable Soil Antibiotic Resistome: A Community of Multi-Drug Resistant Bacteria , 2013, PloS one.
[12] J. Rolain,et al. Evaluation of colistin susceptibility in multidrug-resistant clinical isolates from cystic fibrosis, France , 2013, European Journal of Clinical Microbiology & Infectious Diseases.
[13] R. Bonomo,et al. Insights into β-Lactamases from Burkholderia Species, Two Phylogenetically Related yet Distinct Resistance Determinants* , 2013, The Journal of Biological Chemistry.
[14] P. Vandamme,et al. Identification and distribution of Achromobacter species in cystic fibrosis. , 2013, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[15] N. Høiby,et al. Respiratory bacterial infections in cystic fibrosis , 2013, Current opinion in pulmonary medicine.
[16] J. Otero,et al. Molecular Characterization of Achromobacter Isolates from Cystic Fibrosis and Non-Cystic Fibrosis Patients in Madrid, Spain , 2013, Journal of Clinical Microbiology.
[17] G. Peirano,et al. Antimicrobial susceptibility and combination testing of invasive Stenotrophomonas maltophilia isolates , 2013, Scandinavian journal of infectious diseases.
[18] H. Nelis,et al. Biofilm-Grown Burkholderia cepacia Complex Cells Survive Antibiotic Treatment by Avoiding Production of Reactive Oxygen Species , 2013, PloS one.
[19] J. Estapé. Molecular typing in bacterial infections. , 2013 .
[20] N. Ketheesan,et al. Bacteraemias in tropical Australia: changing trends over a 10-year period. , 2013, Diagnostic microbiology and infectious disease.
[21] A. Fanton,et al. Epidemiology and resistance of Achromobacter xylosoxidans from cystic fibrosis patients in Dijon, Burgundy: first French data. , 2013, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[22] V. Raia,et al. Rapid identification of Burkholderia cepacia complex species recovered from cystic fibrosis patients using matrix-assisted laser desorption ionization time-of-flight mass spectrometry. , 2013, Journal of microbiological methods.
[23] A P MacGowan,et al. EUCAST expert rules in antimicrobial susceptibility testing. , 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[24] Y. Yau,et al. Biofilm Compared to Conventional Antimicrobial Susceptibility of Stenotrophomonas maltophilia Isolates from Cystic Fibrosis Patients , 2013, Antimicrobial Agents and Chemotherapy.
[25] C. Neuwirth,et al. Innate Aminoglycoside Resistance of Achromobacter xylosoxidans Is Due to AxyXY-OprZ, an RND-Type Multidrug Efflux Pump , 2012, Antimicrobial Agents and Chemotherapy.
[26] M. Gonullu,et al. Clinical and microbiological evaluation of eight patients with isolated Achromobacter xylosoxidans , 2012, Scandinavian journal of infectious diseases.
[27] S. Ichiyama,et al. Molecular characterization of IMP-type metallo-β-lactamases among multidrug-resistant Achromobacter xylosoxidans. , 2012, The Journal of antimicrobial chemotherapy.
[28] M. Almuzara,et al. Achromobacter xylosoxidans: An Emerging Pathogen Carrying Different Elements Involved in Horizontal Genetic Transfer , 2012, Current Microbiology.
[29] H. Jacquier,et al. In vitro antimicrobial activity of "last-resort" antibiotics against unusual nonfermenting Gram-negative bacilli clinical isolates. , 2012, Microbial drug resistance.
[30] Mikala Wang,et al. Multilocus Sequence Analysis of Isolates of Achromobacter from Patients with Cystic Fibrosis Reveals Infecting Species Other than Achromobacter xylosoxidans , 2012, Journal of Clinical Microbiology.
[31] J. Odom,et al. Bacterial biofilm diversity in contact lens-related disease: emerging role of Achromobacter, Stenotrophomonas, and Delftia. , 2012, Investigative ophthalmology & visual science.
[32] I. Gould,et al. Combination Antimicrobial Susceptibility Testing of Multidrug-Resistant Stenotrophomonas maltophilia from Cystic Fibrosis Patients , 2012, Antimicrobial Agents and Chemotherapy.
[33] S. Richter,et al. Evaluation of the Bruker Biotyper and Vitek MS Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry Systems for Identification of Nonfermenting Gram-Negative Bacilli Isolated from Cultures from Cystic Fibrosis Patients , 2012, Journal of Clinical Microbiology.
[34] E. Moore,et al. Stenotrophomonas interspecies differentiation and identification by gyrB sequence analysis. , 2012, FEMS microbiology letters.
[35] S. McColley,et al. Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection. , 2012, American journal of respiratory and critical care medicine.
[36] J. Brooke. Stenotrophomonas maltophilia: an Emerging Global Opportunistic Pathogen , 2012, Clinical Microbiology Reviews.
[37] R. Kessler,et al. Should cystic fibrosis patients infected with Burkholderia cepacia complex be listed for lung transplantation? , 2011, Interactive cardiovascular and thoracic surgery.
[38] R. Albano,et al. Achromobacter xylosoxidans: Characterization of Strains in Brazilian Cystic Fibrosis Patients , 2011, Journal of Clinical Microbiology.
[39] C. Llanes,et al. First Description of an RND-Type Multidrug Efflux Pump in Achromobacter xylosoxidans, AxyABM , 2011, Antimicrobial Agents and Chemotherapy.
[40] J. Turton,et al. Identification of Achromobacter xylosoxidans by detection of the bla(OXA-114-like) gene intrinsic in this species. , 2011, Diagnostic microbiology and infectious disease.
[41] Chia-Jui Yang,et al. Clinical characteristics and outcomes of patients with Burkholderia cepacia bacteremia in an intensive care unit. , 2011, Diagnostic microbiology and infectious disease.
[42] S. Cooreman,et al. Comment on: Newer antibacterial agents and their potential role in cystic fibrosis pulmonary exacerbation management. , 2011, The Journal of antimicrobial chemotherapy.
[43] J. Turnidge,et al. Stenotrophomonas maltophilia: emerging disease patterns and challenges for treatment , 2011, Expert review of anti-infective therapy.
[44] P. Dawyndt,et al. Classification and identification of the Burkholderia cepacia complex: Past, present and future. , 2011, Systematic and applied microbiology.
[45] V. Raia,et al. Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients , 2011, European Journal of Clinical Microbiology & Infectious Diseases.
[46] Microbiologie. Burkholderia cepacia Complex , 2010 .
[47] J. Elborn,et al. Newer antibacterial agents and their potential role in cystic fibrosis pulmonary exacerbation management. , 2010, The Journal of antimicrobial chemotherapy.
[48] Safdar Ali,et al. Soil beneficial bacteria and their role in plant growth promotion: a review , 2010, Annals of Microbiology.
[49] S. Sousa,et al. Burkholderia cepacia Complex: Emerging Multihost Pathogens Equipped with a Wide Range of Virulence Factors and Determinants , 2010, International journal of microbiology.
[50] R. Rajendran,et al. Efflux pumps may play a role in tigecycline resistance in Burkholderia species. , 2010, International journal of antimicrobial agents.
[51] P. Dřevínek,et al. Burkholderia cenocepacia in cystic fibrosis: epidemiology and molecular mechanisms of virulence. , 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[52] S. Gillespie,et al. Approaches to measure the fitness of Burkholderia cepacia complex isolates. , 2010, Journal of medical microbiology.
[53] Ronald N. Jones,et al. Antimicrobial Susceptibilities of a Worldwide Collection of Stenotrophomonas maltophilia Isolates Tested against Tigecycline and Agents Commonly Used for S. maltophilia Infections , 2010, Antimicrobial Agents and Chemotherapy.
[54] Heather K. Allen,et al. Call of the wild: antibiotic resistance genes in natural environments , 2010, Nature Reviews Microbiology.
[55] J. Lynch,et al. Burkholderia cepacia Complex: Impact on the Cystic Fibrosis Lung Lesion , 2009, Seminars in respiratory and critical care medicine.
[56] A. Cheng,et al. Dosing Regimens of Cotrimoxazole (Trimethoprim-Sulfamethoxazole) for Melioidosis , 2009, Antimicrobial Agents and Chemotherapy.
[57] J. M. Dow,et al. The versatility and adaptation of bacteria from the genus Stenotrophomonas , 2009, Nature Reviews Microbiology.
[58] S. Shelburne,et al. Inhaled therapeutics for prevention and treatment of pneumonia , 2009, Expert opinion on drug safety.
[59] M. Barchitta,et al. Acquisition and spread of Acinetobacter baumannii and Stenotrophomonas maltophilia in intensive care patients. , 2009, International journal of hygiene and environmental health.
[60] M. Falagas,et al. Therapeutic options for Burkholderia cepacia infections beyond co-trimoxazole: a systematic review of the clinical evidence. , 2009, International journal of antimicrobial agents.
[61] D. C. Griffith,et al. Aerosol antibiotics: considerations in pharmacological and clinical evaluation. , 2008, Current opinion in biotechnology.
[62] M. Falagas,et al. Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review. , 2008, The Journal of antimicrobial chemotherapy.
[63] Eduardo P C Rocha,et al. The Genome of Burkholderia cenocepacia J2315, an Epidemic Pathogen of Cystic Fibrosis Patients , 2008, Journal of bacteriology.
[64] P. Dawyndt,et al. Matrix-assisted laser desorption ionisation-time-of of-flight mass spectrometry of intact cells allows rapid identification of Burkholderia cepacia complex. , 2008, Journal of microbiological methods.
[65] P. Berche,et al. Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry for Identification of Nonfermenting Gram-Negative Bacilli Isolated from Cystic Fibrosis Patients , 2008, Journal of Clinical Microbiology.
[66] M. Hodson,et al. Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985-2005. , 2008, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[67] C. Woods,et al. Survival after lung transplantation of cystic fibrosis patients infected with Burkholderia cepacia complex. , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[68] J. M. Dow,et al. Interspecies signalling via the Stenotrophomonas maltophilia diffusible signal factor influences biofilm formation and polymyxin tolerance in Pseudomonas aeruginosa , 2008, Molecular microbiology.
[69] S. Bell,et al. Burkholderia cepacia complex epidemiology in persons with cystic fibrosis from Australia and New Zealand. , 2008, Research in microbiology.
[70] G. Valenza,et al. Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis. , 2008, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[71] S. Gillespie,et al. Fluoroquinolone-Resistant Mutants of Burkholderia cepacia , 2007, Antimicrobial Agents and Chemotherapy.
[72] K. Rolston,et al. Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[73] L. Saiman,et al. Antimicrobial Susceptibility and Synergy Studies of Burkholderia cepacia Complex Isolated from Patients with Cystic Fibrosis , 2006, Antimicrobial Agents and Chemotherapy.
[74] R. Zbinden,et al. 16S rRNA Gene Sequencing versus the API 20 NE System and the VITEK 2 ID-GNB Card for Identification of Nonfermenting Gram-Negative Bacteria in the Clinical Laboratory , 2006, Journal of Clinical Microbiology.
[75] Chun-Eng Liu,et al. Alcaligenes xylosoxidans bacteremia: clinical features and microbiological characteristics of isolates. , 2005, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.
[76] D. Kontoyiannis,et al. Nonfermentative gram-negative bacilli in cancer patients: increasing frequency of infection and antimicrobial susceptibility of clinical isolates to fluoroquinolones. , 2005, Diagnostic microbiology and infectious disease.
[77] Joanna B. Goldberg,et al. The multifarious, multireplicon Burkholderia cepacia complex , 2005, Nature Reviews Microbiology.
[78] Ronald N. Jones,et al. Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli. , 2005, International journal of antimicrobial agents.
[79] J. Heesemann,et al. Pitfalls of polymyxin antimicrobial susceptibility testing of Pseudomonas aeruginosa isolated from cystic fibrosis patients. , 2004, The Journal of antimicrobial chemotherapy.
[80] P. Vandamme,et al. Epidemiology and Clinical Course of Burkholderia cepacia Complex Infections, Particularly Those Caused by Different Burkholderia cenocepacia Strains, among Patients Attending an Italian Cystic Fibrosis Center , 2004, Journal of Clinical Microbiology.
[81] G. Di Bonaventura,et al. Biofilm Formation by Stenotrophomonas maltophilia: Modulation by Quinolones, Trimethoprim-Sulfamethoxazole, and Ceftazidime , 2004, Antimicrobial Agents and Chemotherapy.
[82] L. Saiman,et al. Infection Control in Cystic Fibrosis , 2004, Clinical Microbiology Reviews.
[83] Yuko Tanaka,et al. The indirect pathogenicity of Stenotrophomonas maltophilia. , 2003, International journal of antimicrobial agents.
[84] R. Gibson,et al. Pathophysiology and management of pulmonary infections in cystic fibrosis. , 2003, American journal of respiratory and critical care medicine.
[85] Tom Coenye,et al. Burkholderia cenocepacia sp. nov.--a new twist to an old story. , 2003, Research in microbiology.
[86] P. Berche,et al. Use of 16S rRNA Gene Sequencing for Identification of Nonfermenting Gram-Negative Bacilli Recovered from Patients Attending a Single Cystic Fibrosis Center , 2002, Journal of Clinical Microbiology.
[87] M. Martinez,et al. Characterization of Flagella Produced by Clinical Strains of Stenotrophomonas maltophilia , 2002, Emerging infectious diseases.
[88] L. Saiman,et al. Identification and Antimicrobial Susceptibility ofAlcaligenes xylosoxidans Isolated from Patients with Cystic Fibrosis , 2001, Journal of Clinical Microbiology.
[89] Tom Coenye,et al. Taxonomy and Identification of the Burkholderia cepacia Complex , 2001, Journal of Clinical Microbiology.
[90] K. W. Yu,et al. Characteristics of patients with Burkholderia cepacia bacteremia. , 2001, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.
[91] P. Vandamme,et al. DNA-Based Diagnostic Approaches for Identification of Burkholderia cepacia Complex, Burkholderia vietnamiensis, Burkholderia multivorans,Burkholderia stabilis, and Burkholderia cepacia Genomovars I and III , 2000, Journal of Clinical Microbiology.
[92] D. E. Anderson,et al. Stenotrophomonas maltophilia: emergence of multidrug-resistant strains during therapy and in an in vitro pharmacodynamic chamber model , 1996, Antimicrobial agents and chemotherapy.
[93] J. Freney,et al. In vitro susceptibility of Alcaligenes denitrificans subsp. xylosoxidans to 24 antimicrobial agents , 1988, Antimicrobial Agents and Chemotherapy.
[94] M. McKee,et al. Molecular typing in bacterial infections , 2013 .
[95] A. Horsley,et al. Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation. , 2012, The Cochrane database of systematic reviews.
[96] N. Høiby,et al. Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients. , 2010, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[97] M. Almuzara,et al. In vitro susceptibility of Achromobacter spp. isolates: comparison of disk diffusion, Etest and agar dilution methods. , 2010, International journal of antimicrobial agents.
[98] G. Di Bonaventura,et al. Subinhibitory concentrations of moxifloxacin decrease adhesion and biofilm formation of Stenotrophomonas maltophilia from cystic fibrosis. , 2010, Journal of medical microbiology.
[99] R. Ariano,et al. Antibiotic combinations significantly more active than monotherapy in an in vitro infection model of Stenotrophomonas maltophilia. , 2005, Diagnostic microbiology and infectious disease.
[100] M. Ferraro. Performance standards for antimicrobial susceptibility testing , 2001 .